Psilocybin demonstrated preliminary efficacy for alcohol use disorder in a recent randomized clinical trial. The mechanism may lie in its interaction with glutamate receptors in the reward pathway of the brain.
Dr. Alex Kwan shares his insight on the field of preclinical psychedelic research and where he thinks things are headed in the future - in his lab, in drug discovery, and beyond.
Entactogenic drugs like MDMA and psychedelics like psilocybin may be beneficial for a range of psychiatric disorders. Though the pharmacology and subjective effects of entactogens and psychedelics differ, drugs that display qualities of both have received little attention to date.
A slew of contemporary research suggests MDMA’s efficacy as an adjunct in the treatment of PTSD, while little is known concerning the mechanisms at work. Recent investigation into the behavioral neurobiology of MDMA’s ability to facilitate the cessation of fear responses may offer a mechanistic explanation regarding its psychiatric utility.
MDMA-assisted therapy has been on the forefront of psychedelic research for years, but more recently patient safety concerns and research ethics have come into question.
The potential use of serotonergic psychedelic drugs has yet to be explored for treatment of multimodal health issues such as obesity. A new preclinical study aims to explore the effects of psilocybin in rodent food consumption and weight gain.
Prior studies in clinical populations with OCD as well as animal models of this disorder indicate that psilocybin may suppress compulsive behavior. Although efforts to identify the mechanism of psilocybin’s effects are underway, the pharmacological targets underlying its anti-compulsive potential remain elusive.
The potential neurotoxicity of MDMA led to the development of APBs, a family of entactogens whose effect profiles may position them as attractive candidates for the next generation of entactogenic medicines.
We review the rise, fall, and rebirth of the infamous entactogen MDMA, the original ‘love drug’ and a promising tool for use in psychotherapy.
Previous research in people with substance use disorders and animal models of drug addiction indicate that classical psychedelics like LSD and psilocybin may reduce drug use and drug-seeking behavior. However, the mechanism of action underlying the anti-addictive effects of psychedelics remains unknown.
Psychedelic Science Review is working to bring cutting-edge science in the field of psychedelics to the public in the most accessible, thorough and accurate way possible. Join our communities on Facebook, Twitter, LinkedIn and Instagram and share our content with your network to help us bring scientifically-backed information about psychedelics to the world.
NEW! Shop the PSR Supporter Store to show your support for psychedelic science.
